Key Highlights
- Alport syndrome is an inherited disease, with X-linked being the most common type of it, and accounts for approximately 80% of the total cases.
- In the absence of intervention, approximately 90% of males experience kidney failure by the age of 40, whereas females less commonly and more gradually progress to kidney failure.
- The majority of alport syndrome patients remain undiagnosed due to the asymptomatic nature of the disease and misdiagnosis.
- The total number of prevalent cases of alport syndrome in the US were ~67,900 in 2023.
- Alport syndrome affects both men and women in the United States with minimal disparity, although men are slightly more impacted than women.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Alport Syndrome Understanding and Treatment Algorithm
Alport Syndrome Overview and Diagnosis
Alport syndrome is a rare genetic disorder characterized by abnormalities of the inner ear and the eye. The disease is caused by an inherited defect in type IV collagen, a structural material needed for the normal function of different body parts. Alport syndrome can present itself in many forms. This includes X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS). Clinically, it is associated with microscopic hematuria, followed by proteinuria and chronic renal insufficiency with end-stage renal disease in young adults.Diagnosis of Alport syndrome is much more likely when there is a family history of Alport syndrome, early hearing loss, hematuria, or kidney failure with unknown cause. Suspicion of the disease is generally heightened when hearing loss is present. Diagnosis can be confirmed by examination of kidney biopsies, where collagen expression and structural changes to the GBM can be observed by immunofluorescence and electron microscopy, respectively. In the case of X-linked Alport syndrome, immunofluorescence microscopy may be employed on skin biopsies to assess the presence of the type IV collagen a-5 chain. Diagnosis is increasingly confirmed by genetic testing.
Alport Syndrome Epidemiology
The Alport Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.- The total number of prevalent cases of alport syndrome in the 7MM were ~159,000 in 2023.
- Alport syndrome is more prevalent in adult population with ~86% contribution in the 7MM, while pediatric population accounted for ~14% cases.
- The X-linked alport syndrome (XLAS) is most prevalent subtype of alport syndrome with around 11,500 cases in 2023 in the US while autosomal dominant alport syndrome (ADAS) being the least prevalent subtype of alport syndrome.
- In EU4 region, the total prevalent cases were the highest in Germany, with nearly 17,000 cases in 2023, while Spain had the least number of cases in 2023.
Scope of the Report
- The report covers a segment of key events, an executive summary, and a descriptive overview of alport syndrome, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
- A detailed review of the alport syndrome epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
- A detailed review of current challenges in establishing the diagnosis.
Alport Syndrome Report Insights
- Patient Population
- Patient population by gender, type, and age
- Country-wise Epidemiology Distribution
Alport Syndrome Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Alport Syndrome Epidemiology Segmentation
Alport Syndrome Report Assessment
- Epidemiology Segmentation
- Current Diagnostic Practices
FAQs
- What are the disease risk and burdens and of alport syndrome? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to alport syndrome?
- What is the historical and forecasted alport syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Which age group is the largest contributor in patients affected with alport syndrome?
- Which subtype is more prevalent among all the subtypes?
- Why the diagnosed prevalent cases remain very low in the 7MM?
Reasons to buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand Key Opinion Leaders’ perspectives around the epidemiology distribution and country-wise variations.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
1. Key Insights2. Report Introduction3. Executive Summary of Dry Amd4. Epidemiology Methodology9. Publisher Capabilities10. Disclaimer11. About the Publisher
5. Dry Amd Epidemiology Overview at a Glance
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Appendix
List of Tables
List of Figures
